Global stock

NASDAQUSD

Insulet Corp.

PODD

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

63/ 100

Overall score·PODD

Current price

149.26USD

26/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 18,3 a PEG 1,11 působí vzhledem k výraznému růstu příznivě, zatímco P/B 6,9 a EV/EBITDA 16,6 ukazují na stále náročnější ocenění. Růst tržeb je silný a ziskovost solidní, ale cena zůstává pod 200denním průměrem a zadlužení vůči vlastnímu kapitálu je zvýšené.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 53%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Insulet Corp. (PODD) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

63/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

66/100

Slightly positive signal based on current news, price action and the economy.

48/100

A lower score means the stock is expensive relative to the company's earnings and assets.

38% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+24%

How fast the company's revenue grows year on year.

76/100

How much the company earns from each unit of revenue and from invested capital.

62/100

Debt level, share-price volatility and how resilient the company is in bad times.

62/100

AI estimate of management quality, execution and capital allocation.

79/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Ashley A. McEvoy je CEO, prezidentka a členka představenstva; Flavia H. Pease působí jako výkonná viceprezidentka a CFO, Eric Benjamin jako výkonný viceprezident a COO a John Wodick Kapples jako seniorní viceprezident a generální právní zástupce. Strategie společnosti stojí na rozšiřování systému Omnipod a jeho využití v léčbě diabetu.

Articles about Insulet Corp., in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

4 November 2026

in 8 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Insulet Corp. (PODD)?

Insulet Corp. (PODD) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Insulet Corp. price today?

As of 26 October 2026, Insulet Corp. trades at about 149.26 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Insulet Corp.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Insulet Corp. pay a dividend?

Insulet Corp. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Insulet Corp. a good investment in 2026?

Our AI signal currently rates Insulet Corp. as slightly positive (score 66/100). Financial health comes out at 63/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 38 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Insulet Corp.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 8 days

On 4 November 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

Fresh news

Signal 27/10, 12:01

Zpráva označuje Insulet za potenciálně 11% podhodnocený při uvedení Omnipod Discover; pokud se rozšíří adopce, může to podpořit výhled, jinak se ocenění nemusí naplnit.

Cena za 7 i 30 dní roste a trend je vzestupný, což podporuje krátkodobé momentum. RSI 68 a velmi vysoká volatilita ale zvyšují riziko výkyvu; dlouhodobý obraz závisí na přijetí produktů.

Risks: Pokud růst ceny ztratí podporu nebo uvedení Omnipod Discover nepovede k širší adopci, pozitivní výhled zeslábne.

More about the signal

Risks: Pokud růst ceny ztratí podporu nebo uvedení Omnipod Discover nepovede k širší adopci, pozitivní výhled zeslábne.

Signal history· 2

11/1020:0150 · Neutral
Leerink Partners 9. října 2026 snížil cílovou cenu Insulet z 145 na 143 USD; jde o mírně nepříznivý signál analytického ocenění, jehož význam by omezila stabilní provozní výkonnost firmy.
02/1016:0220 · Strongly negative
Insulet čelí tlaku na výkon a nižší sentiment trhu, současný technický obraz vykazuje downtrend a RSI pod 40, volatilita vysoká.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued38% above fair value

108.09

range 86.8 – 137.6

Current price

149.26 USD

26 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

108.09 USD

range 86.8 USD – 137.6 USD

: 12.0%
: 9.5%
: 4.97 USD

Předpokládaný růst FCF 12 % p.a. odráží rychlý růst tržeb, ale zůstává pod úrovní, kterou by naznačoval mimořádný meziroční růst EPS. Diskontní sazba 9,5 % zohledňuje betu mírně nad 1 a finanční riziko; terminální růst 2,5 % odpovídá dlouhodobému tempu ekonomiky.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

4/ 6

6/6 tests available

1. Below DCF fair value

38.1% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

11% above the 1-year low (130.5 USD to 299.2 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 26.4 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 1.1; a lower value means cheaper growth.

6. Analyst price target

12.0% vs. the current price, 23 analysts.

Price vs DCF

Current price

149.3 USD

Low 86.78 USDHigh 137.6 USD

Current priceDCF midpoint: 108.1 USD

Price vs analyst target

Current price

149.3 USD

Low 143.0 USDHigh 215.0 USD

Current priceAverage: 167.2 USD

DCF gap

above range

38.1% above the DCF midpoint (108.1 USD).

Analyst target

+12.0%

Average target 167.2 USD vs. price 149.3 USD.

Analyst consensus

Target range

143.0 USD - 215.0 USD

Coverage

23 analysts

Analyst consensus

2 / 5

Changes 180 d

+0 / -6

EPS next year

18.7%

Revenue next year

13.6%

Valuation multiples

26.4

18.3

6.9

3.2

16.6

1.1

52-week range11% above the low

130.5 USD299.2 USD

329.0%

24.0%

12.3%

26.0%

Price vs 50D6.3%

Price vs 200D-19.6%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení získává body za rozvoj produktového portfolia a expanzi, skóre však snižují vysoká rizika v oblasti práv akcionářů a odměňování vedení.

strong

Omnipod a vlastní technologie automatizovaného dávkování inzulinu vytvářejí diferenciaci a určité náklady na změnu systému, přestože konkurence a závislost na regulaci výhodu omezují.

Information

Type: Global stock
Symbol: PODD
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 26.4x
: 9.8B USD
: 66.7 %
: 1.10

§ Risk profile

Výsledek mohou ovlivnit konkurence v inzulinových pumpách a systémech kontinuálního monitorování glukózy, bezpečnost či spolehlivost zařízení a rozhodnutí regulátorů a zdravotních pojišťoven. Český investor navíc nese měnové riziko USD/CZK a riziko vysokého ocenění růstové akcie.

Ask the AI about Insulet Corp.All signals